Search Results
4 Results Found for “tumour-induced osteomalacia”
Welcome to the summer 2026 issue of touchREVIEWS in Endocrinology. In this issue, we bring together articles that reflect the evolving complexity of endocrine and metabolic disease, while highlighting the growing importance of patient-centred care, translational science and interdisciplinary management. We ...
Pathophysiology of X-linked hypophosphataemia X-linked hypophosphataemia (XLH) is a progressive skeletal disorder, originally defined by Albright in 1937 as hypophosphataemic vitamin D rickets.1Â XLH is the commonest form of inherited rickets/osteomalacia and is an X-linked dominant condition.2Â The most common ...
Welcome to the latest edition of European Endocrinology, which features a range of insightful articles covering several areas of endocrinology. In recent years, a key requirement of clinical trials investigating new antidiabetes agents has been to demonstrate cardiovascular safety. An ...
Oncogenic osteomalcia, also known as tumour-induced osteomalacia (TIO), is a rare paraneoplasatic syndrome with around 350 reported cases.1 TIO initial symptoms are nonspecific and include fatigue, bone pain, muscle weakness, weight, and height loss, and later bone deformity and fractures. It ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
